Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo
Jugal P. Dhandhukia, Pu Shi, Santosh Peddi et al. · Bioconjugate Chemistry · 2017
Recombinant protein-polymer scaffolds such as elastin-like polypeptides (ELPs) offer drug-delivery opportunities including biocompatibility, monodispersity, and multifunctionality. We recently reported that the fusion of FK-506 binding protein 12 (FKBP) to an ELP nanoparticle (FSI) increases rapamycin (Rapa) solubility, suppresses tumor growth in breast cancer xenografts, and reduces side effects observed with free-drug controls. This new report significantly advances this carrier strategy by demonstrating the coassembly of two different ELP diblock copolymers containing drug-loading and tumor-targeting domains. A new ELP nanoparticle (ISR) was synthesized that includes the canonical integrin-targeting ligand (Arg-Gly-Asp, RGD). FSI and ISR mixed in a 1:1 molar ratio coassemble into bifunctional nanoparticles containing both the FKBP domain for Rapa loading and the RGD ligand for integrin binding. Coassembled nanoparticles were evaluated for bifunctionality by performing in vitro cell-binding and drug-retention assays and in vivo MDA-MB-468 breast tumor regression and tumor-accumulation studies. The bifunctional nanoparticle demonstrated superior cell target binding and similar drug retention to FSI; however, it enhanced the formulation potency, such that tumor growth was suppressed at a 3-fold lower dose compared to an untargeted FSI-Rapa control. This data suggests that ELP-mediated scaffolds are useful tools for generating multifunctional nanomedicines with potential activity in cancer.
Cited by 44 works. doi:10.1021/acs.bioconjchem.7b00469
Authors
- Jugal P. Dhandhukia
- Pu Shi
- Santosh Peddi
- Zhe Li
- Suhaas Rayudu Aluri
- Yaping Ju
- Dab Brill
- Wan Wang
- Siti Mohd Janib
- Yi‐An Lin
- Shuanglong Liu
- Honggang Cui
- John Andrew MacKay
References
- Molecular portraits of human breast tumours
- Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
- Ki67 expression in breast cancer
- How to measure and predict the molar absorption coefficient of a protein
- Integrins.
- Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
- A guided tour into subcellular colocalization analysis in light microscopy
- Triple-Negative Breast Cancer
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- Current development of mTOR inhibitors as anticancer agents